Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban versus enoxaparin for prevention of venous thromboembolism after lower limb fracture surgery
IRCT20181128041781N1Phase 3Completed
- Sponsor
- Sabzevar University of Medical Sciences
- Start
- Feb 2019
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in deep vein thrombosis (DVT) and pulmonary embolism (PE) comparing Rivaroxaban arm with Enoxaparin arm (2 arms). Primary endpoints: Deep vein thrombosis and Pulmonary embolism. Started Feb 2019; status: completed.
02
Drugs
rivaroxabanenoxaparin
03
Conditions
deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on IRCT20181128041781N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20181128041781N1.